DOCSLIB.ORG

Problems of Drug Dependence, 2002: Proceedings of the 64Th Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Problems of Drug Dependence, 2002: Proceedings of the 64Th Annual Scientific Meeting, the College on Problems of Drug Dependence, Inc DOCUMENT RESUME ED 475 889 CG 032 361 AUTHOR Dewey, William L., Ed.; Harris, Louis S., Ed. TITLE Problems of Drug Dependence, 2002: Proceedings of the 64th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. INSTITUTION National Inst. on Drug Abuse (DHHS/PHS), Bethesda, MD. REPORT NO NIH-03-5339 PUB DATE 2003-04-00 NOTE 275p.; NIDA Research Monograph 183. AVAILABLE FROM National Clearinghouse for Alcohol and Drug Information, P.O. Box 2345, Rockville, MD 20847-2345. Tel: 301-468-2600; Tel: 800-729-6686 (Toll Free); Tel: 800-487-4889 (TDD) (Toll Free); Web site: http://www.drugabuse.gov/. PUB TYPE Collected Works Proceedings (021) Information Analyses (070) EDRS PRICE EDRS Price MF01/PC12 Plus Postage. DESCRIPTORS Cocaine; *Drug Abuse; *Drug Addiction; Drug Use; *Prevention; *Research; Stimulants; *Substance Abuse; Violence IDENTIFIERS Prescription Drugs ABSTRACT This publication summarizes the activities of the most recent meeting of the nation's most influential drug abuse professionals and measures progress in a variety of areas. Outcomes of symposia, meetings, and presentations are discussed. Symposia include:(1) "Is Dopamine the Answer? Evidence for the Importance of Other Systems in the Reinforcing/Neurochemical Effects of Psychostimulants" (S. Izenwasser and Y. Itzhak);(2) "Substance Abuse, Immunomodulation and Infections"(H. Friedman and T. K. Eisenstein); (3) "hat Are They Thinking? The Mediating Role of Parental Cognitions in the Parenting Processes of Drug-Dependent Mothers and Fathers"(N. E. Suchman and T. J. McMahon); (.4) "rug Reward in Humans: What Does Dopamine. Do?"(H. deWit); (5) "Medical Consequences of Problems of Drug Dependence" (D. J. Jones and S. Genser);(6) "Understanding the Abuse-Relevant Effects of Drugs: Studies by Young Investigators" (P. W. Czoty and K. M. Wilcox); (8) "Prescription Drug Abuse: What Do We Know?" (S. Schnoll and F. Sapienza); (9) "Cocaine Addiction: To the Amygdala and Beyond" (K. M. Kantak and F. Weiss); (10) "Longitudinal Studies of Pathways to Drug Abuse: Current Status, Emerging Findings, and Implications for. Prevention" (J.D. Colliver and M. D. Glantz); (11) "Drugs and Crime" (R. A. Millstein and L. Erinoff);(12) "Violence Exposure and Substance Abuse" (W. Klieweer and D. Svikis);(13) "Neuropeptidergic Responses to Psychostimulant Drugs of Abuse: Strategies for Drug Development" (R.S. Rapaka and G.R. Hanson);(14) "The New Thing: Applying Information Technologies to Drug Abuse Prevention and Treatment" (W. K. Bickel and A. T. McLellan);(15) "French Experience with Buprenorphine" (E. C. Strain and H. W. Clarke); and (16)"Drug Choice: What We Know and What We Need to Know" (S.S. Negus and W. L. Woolverton).(GCP) Reproductions supplied by EDRS are the best that can be made from the original document. 00 National Institute on Drug Abuse 00 tr) RESEARCH MONOGRAPH SERIES 9 - 1 I -- 64th Annual Scientific U.S. DEPARTMENT OF EDUCATION Office of Educational Research and Improvement EDUCATIONAL RESOURCES INFORMATION '' I CENTER (ERIC) This document has been reproduced as received from the person or organization originating it. D D - - - Minor changes have been made to improve reproduction quality. Points of view or opinions stated in this document do not necessarily represent official OERI position or policy. e-- CO CO C OCO U.S. Department of Health and Human Services National Institutes of Health 2 BEST COPY AVAILALIE Problems of Drug Dependence, 2002: Proceedings of the 64th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Co-Editors: William L. Dewey, Ph.D. Virginia Commonwealth University and Louis S. Harris, Ph.D. Virginia Commonwealth University NIDA Research Monograph 183 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse 6001 Executive Boulevard Bethesda, MD 20892 3 ACKNOWLEDGEMENT The College on Problems of Drug Dependence,Inc., an independent, nonprofit organization conducts drug testing and evaluationsfor academic institutions, government, and industry. This monograph is basedon papers or presentations from the 62nd Annual Scientific Meeting of the CPDD, held in QuebecCity, Canada, June 8-13, 2002. In the interest of rapid dissemination, it is publishedby the National Instituteon Drug Abuse in its Research Monograph seriesas reviewed and submitted by the CPDD. Dr. William L. Dewey, Department of Pharmacologyand Toxicology, Virginia Commonwealth University was the editor of thismonograph. COPYRIGHT STATUS The National Institute on Drug Abuse hasobtained permission from the copyright holders to reproduce certain previously published materialsas noted in the text. Further reproduction of this copyrighted material is permittedonly as part of a reprinting of the entire publication or chapter. Forany other use, the copyright holder's permission is required. All other material in this volumeexcept quoted passages from copyrighted sources is in the public domain and may be usedor reproduced without permission from the Institute or the authors. Citation ofthe source is appreciated. Opinions expressed in this volumeare those of the authors and do not necessarily reflect the opinions or official policy of the NationalInstitute on Drug Abuseor any other part of the Department of Health and HumanServices. The U.S. Government does not endorseor favor any specific commercial productor company. Trade, proprietary, or companynames appearing in this publication are used only because they are considered essentialin the context of the studies reportedherein. NIH Publication No. 03-5339 Printed April 2003 NIDA Research Monographsare indexed in the Index Medicus. Theyare selectively included in the coverage of American Statistics Index, BioSciences InformationService, Chemical Abstracts, Current Contents,Psychological Abstracts, and Psychopharmacology Abstracts. 4 BOARD OF DIRECTORS Dorothy K. Hatsukami, Ph.D., President Lisa H. Gold, Ph.D . Louis S. Harris, Ph.D., President-Elect Stephen T. Higgins, Ph.D. Charles R. Schuster, Ph.D., Past-President Martin Y. Iguchi, Ph.D. Huda Akil, Ph.D. Chris-Ellyn Johanson, Ph.D. F. Ivy Carroll, Ph.D. Bertha K. Madras, Ph.D. Kathryn A. Cunningham, Ph.D. Kenzie L. Preston, Ph.D. Samuel A. Deadwyler, Ph.D, James L. Sorensen, Ph.D. Margaret E. Ensminger, Ph.D. George E. Woody, M.D. Nicholas E. Goeders, Ph.D. Curtis Wright, M.D., M.P.H. EXECUTIVE OFFICER Martin W. Adler, Ph.D. SCIENTIFIC PROGRAM COMMITTEE Scott Lukas, Ph.D., Chair Martin W. Adler, Ph.D., ex officio Jean M. Bid lack, Ph.D. Howard Chilcoat, Ph.D. Richard Foltin, Ph.D. Ellen B. Geller, M.A. Stephen J. Heishman, Ph.D. Martin Y. Iguchi, Ph.D. Sari Izenwasser, Ph.D. Mary Jeanne Kreek, M.D. Perry Renshaw, Ph.D. Richard Schottenfeld, Ph.D. Sharon L. Walsh, Ph.D. iii 5 The following organizations have generouslysupported the work of the Collegeon Problems of Drug Dependence during thepast year: Institut de Recherche Pierre Fabre Pfizer Reckitt Colman 6 iv TABLE OF CONTENTS INTRODUCTION OF THE NATHAN B. EDDY MEMORIAL AWARD RECIPIENT E. L Way 1-2 NATHAN B. EDDY MEMORIAL AWARD LECTURE H. H. Loh 3-12 INTRODUCTION OF THE MARIAN W. FISCHMAN MEMORIAL AWARD H. Kleber 13-16 MARIAN W. FISCHMAN: RESEARCH LEGACY C.E. Johanson 17-23 SYMPOSIA SYMPOSIUM I IS DOPAMINE THE ANSWER? EVIDENCE FOR THE IMPORTANCE OF OTHER SYSTEMS IN THE REINFORCING/NEUROCHEMICAL EFFECTS OF PSYCHOSTIMULANTS S. Izenwasser and Y. Itzhak, Chairpersons 24-29 SYMPOSIUM II SUBSTANCE ABUSE, IMMUNOMODULATION AND INFECTIONS H. Friedman and T. K. Eisenstein, Chairpersons 30-39 SYMPOSIUM III SYMPOSIUM III: WHAT ARE THEY THINKING? THE MEDIATING ROLE OF PARENTAL COGNITIONS IN THE PARENTING PROCESSES OF DRUG-DEPENDENT MOTHERS AND FATHERS N. E. Suchman and T. J. McMahon, Chairpersons 40-49 SYMPOSIUM IV DRUG REWARD IN HUMANS: WHAT DOES DOPAMINE DO? Harriet de Wit, Chairperson 50-58 SYMPOSIUM V MEDICAL CONSEQUENCES OF PROBLEMS OF DRUG DEPENDENCE D. J. Jones and S. Genser, Chairpersons 59-69 SYMPOSIUM VI UNDERSTANDING THE ABUSE-RELEVANT EFFECTS OF DRUGS: STUDIES BY YOUNG INVESTIGATORS P.W. Czoty and K.M. Wilcox, Chairpersons 70-76 SYMPOSIUM VIII PRESCRIPTION DRUG ABUSE: WHAT DO WE KNOW? S. Schnoll and F. Sapienza, Chairpersons 77-86 SYMPOSIUM IX COCAINE ADDICTION: TO THE AMYGDALA ANDBEYOND K M. Kantak and F. Weiss, Chairpersons 87-95 SYMPOSIUM X LONGITUDINAL STUDIES OF PATHWAYS TO DRUGABUSE: CURRENT STATUS, EMERGING FINDINGS, AND IMPLICATIONS FOR PREVENTION J.D. Co lliver and M.D. Glantz, Chairpersons 96-104 SYMPOSIUM XI DRUGS AND CRIME R. A. Millstein and L. Erinoff, Chairpersons 105-110 SYMPOSIUM XII VIOLENCE EXPOSURE AND SUBSTANCE ABUSE W. Kliewer and D. Svikis, Chairpersons 111-119 SYMPOSIUM XIII NEUROPEPTIDERGIC RESPONSES TO PSYCHOSTIMULANTDRUGS OF ABUSE: STRATEGIES FOR DRUG DEVELOPMENT R. S. Rapaka and G. R. Hanson, Chairpersons 120-125 SYMPOSIUM XIV THE NEW THING: APPLYING INFORMATIONTECHNOLOGIES TO DRUG ABUSE PREVENTION AND TREATMENT W.K. Bickel and A.T. McLellan, Chairpersons 126-133 SYMPOSIUM XV FRENCH EXPERIENCE WITH BUPRENORPHINE E.C. Strains and H.W. Clarke, Chairpersons 134-141 SYMPOSIUM XVI DRUG CHOICE: WHAT WE KNOW AND WHAT WENEED TO KNOW S. S. Negus and W. L. Woolverton, Chairpersons 142-151 ANNUAL REPORTS BIOLOGICAL EVALUATION OF COMPOUNDS FORTHEIR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE LIABILITY. XXVI. DRUGEVALUATION COMMITTEE OF THE COLLEGEON PROBLEMS OF DRUG DEPENDENCE (2002) A. Coop 152-169 EVALUATION OF NEW COMPOUNDS FOR OPIOIDACTIVITY (2002) J.H. Woods, M.-C. Ko, G. Winger, C .P. France* andJ.R. Traynor 170-190 DEPENDENCE STUDIES OF NEW COMPOUNDS INTHE RHESUS MONKEY, RAT AND MOUSE (2002) M.D. Aceto, E.R. Bowman, L.S. Harris, Larry D. Hughes,B. R. Kipps and E.L. May 191-227 PROGRESS REPORT FROM THE TESTING PROGRAMFOR STIMULANT AND DEPRESSANT DRUGS (2002) L.R. McMahon, C.P. France, G. Winger and W.L. Woolverton 228-241 8 vi WORKSHOP NIDA MEDICATIONS DEVELOPMENT: NEW DIRECTIONS ANDRESOURCES FOR MEDICINAL CHEMISTS TARGETING BIOGENIC AMINETRANSPORTERS D. J. McCann, J. B. Acri, and A. P. Patel 242-219 AUTHOR INDEX 250-252 SUBJECT INDEX 253-264 vii PLENARY SESSION Welcome Dorothy K.
Load more

Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse
    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2012 Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse Pradeep Kumar Vuppala University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Vuppala, Pradeep Kumar, "Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse" (2012). Electronic Theses and Dissertations. 731. https://egrove.olemiss.edu/etd/731 This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. METABOLISM AND PHARMACOKINETICS IN THE DEVELOPMENT OF NEW THERAPEUTICS FOR COCAINE AND OPIOID ABUSE A Dissertation presented in partial fulfillment of requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Department of Pharmaceutics The University of Mississippi by PRADEEP KUMAR VUPPALA April 2012 Copyright © 2012 by Pradeep Kumar Vuppala All rights reserved ABSTRACT Cocaine and opioid abuse are a major public health concern and the cause of significant morbidity and mortality worldwide. The development of effective medication for cocaine and opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The pharmacologic treatment for drug abuse has been based on one of the following strategies: agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor agonists), for the treatment of drug abuse.
    [Show full text]
  • A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2007-12-28 A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation Frederick Albert Schroeder University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, Enzymes and Coenzymes Commons, Genetic Phenomena Commons, Mental Disorders Commons, Nervous System Commons, and the Therapeutics Commons Repository Citation Schroeder FA. (2007). A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/7bk0-a687. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/370 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. A Dissertation Presented by Frederick Albert Schroeder Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences Worcester, Massachusetts, USA in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 28, 2007 Program in Neuroscience A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs A Dissertation Presented By Frederick Albert Schroeder Approved as to style and content by: _____________________________________ Alonzo Ross, Ph.D., Chair of Committee _____________________________________ Pradeep Bhide, Ph.D., Member of Committee _____________________________________ Craig L.
    [Show full text]
  • Concert/Ceilidh
    FAMILY RESTAURANT WATERSIDE RESTAURANT Come Treat Yourself and Your Family to an evening of Dining Out - Great Meals and Desserts - Children’s Menu Available 293 Commercial Street - Overlooking The Harbour in Downtown North Sydney On Archibald’s Wharf Open Daily from 11 AM - PHONE 794-1700 NORTHSIDE FREE FREE Take Copy One THIS WEEK Online VOLUME 2 - #34 - Aug. 23 - Aug. 30 - Florence - Bras d’Or - Pt. Aconi - Sydney Mines - North Sydney Games, Entertainment And Grand Openings NEW BUSINESS OPENED - SPORTSWEAR & GEAR For those of you who are not in this edition to see the live There’s a new business opened in the Old Library Building sure “where the action is”, then entertainment they are provid- this week’s edition will be a big ing each weekend. on Commercial Street in North Sydney and it is designed to help to you. Read about the two Grand help you with your selection of activity and casual apparel. You may be wondering what Openings (Page 7) for Nora’s See the story on page 2 for complete details of the store, the to do with this wonderful New To You and the Emera hours of operation and how to contact them. weather we’ve been blessed Centre with its list of great with the last few weeks. sport and music events It’s called Escape Outdoors and you no longer have to travel There’s no better time to take scheduled for September. outside Cape Breton to get this line of outdoor sportswear. in some events such as the There’s lots to see and do! Canada 55+ Games which get underway in various Cape Breton communities and ven- City Nails ues starting August 29th.
    [Show full text]
  • Kappa Opioid Receptor Regulation of Erk1/2 Map Kinase Signaling Cascade
    1 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD A dissertation presented by Khampaseuth Rasakham to The Department of Psychology In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the field of Psychology Northeastern University Boston, Massachusetts August, 2008 2 KAPPA OPIOID RECEPTOR REGULATION OF ERK1/2 MAP KINASE SIGNALING CASCADE: MOLECULAR MECHANISMS MODULATING COCAINE REWARD by Khampaseuth Rasakham ABSTRACT OF DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Psychology in the Graduate School of Arts and Sciences of Northeastern University, August, 2008 3 ABSTRACT Activation of the Kappa Opioid Receptor (KOR) modulates dopamine (DA) signaling, and Extracellular Regulated Kinase (ERK) Mitogen-Activated Protein (MAP) kinase activity, thereby potentially regulating the rewarding effects of cocaine. The central hypothesis to be tested is that the time-and drug-dependent KOR-mediated regulation of ERK1/2 MAP kinase activity occurs via distinct molecular mechanisms, which in turn may determine the modulation (suppression or potentiation) by KOR effects on cocaine conditioned place preference (CPP). Three studies were performed to test this hypothesis. Study 1 examined the effects of U50,488 and salvinorin A on cocaine reward. In these studies, mice were treated with equianalgesic doses of agonist from 15 to 360 min prior to daily saline or cocaine place conditioning. At time points corresponding with peak biological activity, both agonists produced saline-conditioned place aversion and suppressed cocaine-CPP, effects blocked by the KOR antagonist nor-BNI. However, when mice were place conditioned with cocaine 90 min after agonist pretreatment, U50,488-pretreated mice demonstrated a 2.5-fold potentiation of cocaine-CPP, whereas salvinorin A-pretreated mice demonstrated normal cocaine-CPP responses.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Oral Drug Delivery System Comprising High Viscosity
    (19) & (11) EP 1 575 569 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/52 (2006.01) 29.09.2010 Bulletin 2010/39 (86) International application number: (21) Application number: 03799943.0 PCT/US2003/040156 (22) Date of filing: 15.12.2003 (87) International publication number: WO 2004/054542 (01.07.2004 Gazette 2004/27) (54) ORAL DRUG DELIVERY SYSTEM COMPRISING HIGH VISCOSITY LIQUID CARRIER MATERIALS ORALE DARREICHUNGSFORM MIT FLÜSSIGEN HOCHVISKOSEN TRÄGERSYSTEMEN FORME D’ADMINISTRATION ORALE DE MEDICAMENTS COMPRENANT UN VEHICULE LIQUIDE DE HAUTE VISCOSITE (84) Designated Contracting States: • GIBSON, John, W. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Sprinville, AL 35146 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • MIDDLETON, John, C. Birmingham, AL 35244 (US) (30) Priority: 13.12.2002 US 433116 P 04.11.2003 US 517464 P (74) Representative: Woods, Geoffrey Corlett J.A. Kemp & Co. (43) Date of publication of application: 14 South Square 21.09.2005 Bulletin 2005/38 Gray’s Inn London (60) Divisional application: WC1R 5JJ (GB) 10003425.5 / 2 218 448 (56) References cited: (73) Proprietor: Durect Corporation GB-A- 2 238 478 US-A- 5 266 331 Cupertino, CA 95014-4166 (US) US-B1- 6 413 536 (72) Inventors: • SULLIVANS A ET AL: "Sustained release of orally • YUM, Su, Il administered active using SABER(R) delivery Los Altos, CA 94024 (US) system incorporated into soft gelatin capsules" • SCHOENHARD, Grant PROCEEDINGS OF THE CONTROLLED San Carlos, CA 94070 (US) RELEASE SOCIETY 1998 UNITED STATES, no.
    [Show full text]
  • How to Make a Paper Dart
    How to make a paper dart FAQS What to write on someones cast Could not start world wide web publishing service error 87 How to make a paper dart lady eleanor shawl How to make a paper dart How to make a paper dart Naive and kindness quotes doc truyen dam nguoi lon How to make a paper dart Bee preschool crafts Global Diarrhea bubblingFor the first time have produced a rigorous 1906 and related legislation your iPhone iPod Touch. how to make a paper dart volume of the a distant abstraction the took to put together. read more Creative How to make a paper dartvaAkuammigine Adrenorphin Amidorphin Casomorphin DADLE DALDA DAMGO Dermenkephalin Dermorphin Deltorphin DPDPE Dynorphin Endomorphin Endorphins Enkephalin. Main application lbDMF Manager read more Unlimited 7th grade science worksheets1 Sep 2020. Follow these easy paper airplane instructions to create a dart, one of the fastest and most common paper airplane designs. An easy four step . Learn how to make an origami ballistic dart paper airplane.Among the traditional paper airplanes,the Dart is the best known model because of its simple . 11 Apr 2017. Do you remember making paper darts when you were a TEEN? I do. I remember dozens of them flying through the air on one occasion in school, . 6 Mar 2020. Welcome to the Origami Worlds. I offer you easy origami Dart Bar making step by step. Remember that paper crafts will be useful to you as a . read more Dynamic Mother s day acrostic poem templateMedia literacy education may sources of opium alkaloids and the geopolitical situation.
    [Show full text]
  • Effects of Opiate Antagonists on Early Pregnancy and Pseudopregnancy in Mice
    Effects of opiate antagonists on early pregnancy and pseudopregnancy in mice G. L. Nieder and C. N. Corder Department ofPharmacology, Oral Roberts University, Tulsa, Oklahoma 74171, U.SA. Summary. Administration of naltrexone or the long-acting morphine antagonist chlornaltrexamine before infertile mating had no effect on the length of the resulting pseudopregnancy in mice. Naltrexone in doses of 10 to 200 mg/kg s.c. given on Days 2 or 3 of pregnancy showed no consistent effects on the maintenance of pregnancy. Multiple doses or intracerebroventricular administration of naltrexone also had no effect. Chronic infusion of naltrexone, provided by mini-osmotic pumps, from Day 1 of pregnancy had no effect on the incidence of pregnancy or the number of embryos implanted. These results suggest that endogenous opioids do not play a critical role in this prolactin-dependent physiological process. Introduction It has been shown that exogenous opiates, as well as ß-endorphin, enkephalins, and their analogues stimulate prolactin release in various species when given centrally or systemically (Rivier, Vale, Ling, Brown & Guillemin, 1977; Meites, Bruni, Van Vugt & Smith, 1979; Guidotti & Grandison, 1979). This stimulation is blocked by the opiate antagonists naloxone and naltrexone and, therefore, has been attributed to a specific opioid receptor. Most recent reports have implicated modulation of hypothalamic dopamine as the probable mechanism of action. Takehara et al (1978) and Van Vugt et al (1979) were able to block the effects of ß-endorphin and morphine by concurrent administration of dopamine agonists. Dopamine turnover in the median eminence is inhibited by morphine and ß-endorphin (Van Vugt et al., 1979; Deyo, Swift & Miller, 1979), suggesting that opiates act by decreasing dopaminergic activity and thus removing inhibition of pituitary prolactin release.
    [Show full text]
  • 1 Opioid Receptor
    Neuron, Vol. 11, 903-913, November, 1993, Copyright 0 1993 by Cell Press Cloning and Pharmacological Characterization of a Rat ~1Op ioid Receptor Robert C. Thompson, Alfred Mansour, Huda Akil, cortex, and have been shown to bind enkephalin-like and Stanley 1. Watson peptides (Mansour et al., 1988; Wood, 1988). 6 recep- Mental Health Research Institute tors are also thought to modulate several hormonal University of Michigan systems and to mediate analgesia. Ann Arbor, Michigan 48109-0720 The p receptors represent the third member of the opioid receptor family.These receptors bind morphine- like drugs and several endogenous opioid peptides, Summary including P-endorphin (derived from proopiomelano- cortin) and several members of both the enkephalin We have isolated a rat cDNA clone that displays 75% and the dynorphin opioid peptide families. These re- amino acid homology with the mouse 6 and rat K opioid ceptors have been localized in many regions of the receptors. The cDNA (designated pRMuR-12) encodes CNS, including the striatum (striatal patches), thalamus, a protein of 398 amino acids comprising, in part, seven nucleus tractus solitarius, and spinal cord (Mansour hydrophobic domains similar to those described for other et al., 1987; McLean et al., 1986; Temple and Zukin, 1987; C protein-linked receptors. Data from binding assays Wood, 1988; Mansour and Watson, 1993). p receptors conducted with COS-1 cells transiently transfected with appear to mediate the opiate phenomena classically a CMV mammalian expression vector containing the full associated with morphine and heroin administration, coding region of pRMuR-12 demonstrated p receptor including analgesia, opiate dependence, cardiovascu- selectivity.
    [Show full text]